Stellar Biotech: Jumps on positive study news for protein product

Neovacs SA

05/07/2018 14:09

** Shares of Stellar Biotechnologies  SBOT.O  jump 7.7 pct
in heavy premarket trading
    ** The pharmaceutical ingredients maker's customer and JV
partner, Neovacs S.A.  ALNEV.PA  released positive results from
a phase 2b study on IFNalpha Kinoid in patients with moderate to
severe lupus  urn:newsml:reuters.com:*:nGNE9r5D68
    ** Stellar Biotech in particular notes Neovacs' reported
potent and long-lasting biological activity as well as safety
profile of their therapeutic vaccine, which utilizes Stellar's
KLH as a carrier molecule  urn:newsml:reuters.com:*:nPn3Nc2L7a
    ** Stellar recently reported successful completion of a
study on the molecular composition of its KLH protein products;
KLH used as a pharma ingredient in research and for vaccines
 urn:newsml:reuters.com:*:nL4N1TN4CV
    ** Trading vols in SBOT approaching 800k, making them the
4th most heavily traded US stock; 10-day moving avg is 4.6 mln
    ** Despite a ~27 pct surge on the KLH news on June 21, SBOT
is still down ~68 pct this year as of Tuesday's close    

 (Reporting by Savio D'Souza)
 ((RM:savio.dsouza.thomsonreuters.com@reuters.net))